For CD8+ T cells, DMEM-treated AD-MSCs reduced CD25 expression from 55–76% in monoculture to 12.6–22.7% (early) and 12.1–20.8% (late) co-cultures. The gene discussed is CD8A; the disease is Alzheimer disease.